Perspective Therapeutics, Inc. (CATX) – What Are Researchers Thinking About This Stock?

Posted by Brian Himes on Oct 12th, 2026

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.50.

A number of research firms have recently weighed in on CATX. Piper Sandler cut their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, October 7th. William Blair began coverage on Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating for the company. Bank of America cut their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, September 15th.

Check Out Our Latest Stock Analysis on Perspective Therapeutics

Perspective Therapeutics Stock Performance

NYSEAMERICAN CATX opened at $2.66 on Wednesday. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16. The company has a 50 day moving average of $2.94 and a 200-day moving average of $3.39.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. Sell-side analysts expect that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Commodore Capital LP acquired a new position in Perspective Therapeutics during the first quarter worth about $26,424,000. Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after acquiring an additional 2,864,582 shares during the last quarter. Avidity Partners Management LP boosted its stake in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares in the last quarter. Spruce Street Capital LP acquired a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $10,955,000. Finally, Yu Fan acquired a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $4,401,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.